The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine.

abstract：BACKGROUND AND OBJECTIVE:Clearance is an important pharmacokinetic concept for scaling dosage, understanding the risks of drug-drug interactions and environmental risk assessment in children. Accurate clearance scaling to children requires prior knowledge of adult clearance mechanisms and the age-dependence of physiolo...

journal_title：Clinical pharmacokinetics

authors： Edginton AN,Schmitt W,Voith B,Willmann S

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Antihistamines (histamine H(1) receptor antagonists) are effective and convenient drugs for the treatment of allergic conjunctivitis. Because of the short duration of action generally observed for drugs administered topically to the eye, the oral route is often preferred. However, the presence of a selective...

journal_title：Clinical pharmacokinetics

authors： Grumetto L,Cennamo G,Del Prete A,La Rotonda MI,Barbato F

更新日期：2002-01-01 00:00:00

abstract：:The prevalence of HIV-associated neurocognitive disorder (HAND) is increasing despite the widespread use of combination antiretroviral therapy (ART). Initial reports suggest that the use of antiretrovirals with good central nervous system (CNS) penetration leads to better neurocognitive outcomes, but this has not yet ...

journal_title：Clinical pharmacokinetics

authors： Decloedt EH,Rosenkranz B,Maartens G,Joska J

更新日期：2015-06-01 00:00:00

abstract：:Antipsychotics may cause serious adverse cardiovascular effects, including prolonged QT interval and sudden death. This review considers antipsychotic-induced cardiovascular events from three perspectives: high-risk drugs, high-risk individuals and high-risk drug interactions. Pharmacokinetic drug interactions involvi...

journal_title：Clinical pharmacokinetics

authors： Brown CS,Farmer RG,Soberman JE,Eichner SF

更新日期：2004-01-01 00:00:00

abstract：:Voriconazole is both a substrate and a potent inhibitor of cytochrome P450 (CYP) 3A. It has a high bioavailability and non-linear pharmacokinetics. We investigated the pharmacokinetics and metabolism of 50 mg and 400 mg doses of intravenous and oral voriconazole in 14 healthy volunteers. Concurrently, we determined sy...

journal_title：Clinical pharmacokinetics

authors： Hohmann N,Kocheise F,Carls A,Burhenne J,Weiss J,Haefeli WE,Mikus G

更新日期：2016-12-01 00:00:00

abstract：OBJECTIVE:To determine the multiple dose pharmacokinetics of a new extended release (ER) capsule formulation of tolterodine, compared with the existing immediate release (IR) tablet, in healthy volunteers. DESIGN:Nonblind, randomised, 2-way crossover trial. PARTICIPANTS:19 healthy volunteers (7 females, 12 males), me...

journal_title：Clinical pharmacokinetics

authors： Olsson B,Szamosi J

更新日期：2001-01-01 00:00:00

abstract：:Data on the pharmacokinetics of ofloxacin in chronic renal failure, in patients who were not dialysed or were receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), are reviewed. In addition, a large pool of data obtained in patients with a wide range of renal dysfunction is provided. The good ab...

journal_title：Clinical pharmacokinetics

authors： Lameire N,Rosenkranz B,Malerczyk V,Lehr KH,Veys N,Ringoir S

更新日期：1991-11-01 00:00:00

abstract：:In the last 15 years the role of opioids in anaesthesia management has undergone dramatic change. Initially used as premedicants, or adjuvants to inhalation anaesthetic agents or as analgesics for postoperative pain relief, narcotics have now evolved into primary anaesthetic agents, primarily because of their ability ...

journal_title：Clinical pharmacokinetics

authors： Davis PJ,Cook DR

更新日期：1986-01-01 00:00:00

abstract：:Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusi...

journal_title：Clinical pharmacokinetics

authors： Graham GG,Punt J,Arora M,Day RO,Doogue MP,Duong JK,Furlong TJ,Greenfield JR,Greenup LC,Kirkpatrick CM,Ray JE,Timmins P,Williams KM

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated clinical activity in a number of different cancer types. The objectives of this study were to characterize the pharmacokinetics of abemaciclib in cancer patients using population pharmacokinetic (popPK) modelin...

journal_title：Clinical pharmacokinetics

authors： Tate SC,Sykes AK,Kulanthaivel P,Chan EM,Turner PK,Cronier DM

更新日期：2018-03-01 00:00:00

abstract：:25 patients with different degrees of chronic stable renal failure received oral treatment with cimetidine over 6 days and a final dose in the morning of day 7. The doses of cimetidine were reduced according to the degree of renal failure. Plasma concentrations of cimetidine were determined before the morning dose on ...

journal_title：Clinical pharmacokinetics

authors： Larsson R,Norlander B,Bodemar G,Walan A

更新日期：1981-07-01 00:00:00

abstract：:It should be recognized that children are not small adults, hence dosing in children should not be a 'small adult dose'. A mean population dose in all age groups is just an average dose and not necessarily the best or the correct dose for a given patient. The dose of a drug varies from patient to patient and individua...

journal_title：Clinical pharmacokinetics

authors： Mahmood I

更新日期：2014-04-01 00:00:00

abstract：:In the original publication, Page 3, Sect. 4.3, the first sentence was incorrectly published. ...

journal_title：Clinical pharmacokinetics

authors： Martin JH,Schneider J,Lucas CJ,Galettis P

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:People living with human immunodeficiency virus are ageing under combination antiretroviral treatments but data on drug exposure in serum and cerebrospinal fluid are limited. Dolutegravir is a widely used second-generation integrase strand transfer inhibitor: conflicting data suggest that neuropsychiatric si...

journal_title：Clinical pharmacokinetics

authors： Calcagno A,Moltó J,Borghetti A,Gervasoni C,Milesi M,Valle M,Avataneo V,Alcantarini C,Pla-Junca F,Trunfio M,D'Avolio A,Di Giambenedetto S,Cattaneo D,Di Perri G,Bonora S

更新日期：2021-01-01 00:00:00

abstract：:20 routine patients with endogenous depression were investigated in a kinetic and 4 week treatment study. Steady-state plasma nortriptyline concentrations above 200 microgram/L were associated with a highly significant poorer therapeutic outcome. The correlations between the 24, 48 and 72 hour concentrations and stead...

journal_title：Clinical pharmacokinetics

authors： Montgomery SA,McAuley R,Montgomery DB,Braithwaite RA,Dawling S

更新日期：1979-03-01 00:00:00

abstract：:Since its discovery in 1970, and introduction into clinical practice in 1978, cyclosporin has become the most important immunosuppressive drug used to prevent organ transplant rejection. This has been achieved by virtue of the improved graft survival rates and adverse effect profiles in patients when compared with tha...

journal_title：Clinical pharmacokinetics

authors： Jones TE

更新日期：1997-05-01 00:00:00

abstract：:Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors. Following a oral dose of buspirone 20...

journal_title：Clinical pharmacokinetics

authors： Mahmood I,Sahajwalla C

更新日期：1999-04-01 00:00:00

abstract：:Due to concern and debate in the epilepsy medical community and to the current interest of the US Food and Drug Administration (FDA) in revising approaches to the approval of generic drugs, the FDA is currently supporting ongoing bioequivalence studies of antiepileptic drugs, the EQUIGEN studies. During the design of ...

journal_title：Clinical pharmacokinetics

authors： Diaz FJ,Berg MJ,Krebill R,Welty T,Gidal BE,Alloway R,Privitera M

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The likelihood of detecting a therapeutic signal of an effective drug for schizophrenia is impeded by a high placebo effect and by high dropout of patients. Several unsuccessful trials of schizophrenia, at least partly due to highly variable placebo effects, have indicated the necessity for a ...

journal_title：Clinical pharmacokinetics

authors： Pilla Reddy V,Kozielska M,Johnson M,Suleiman AA,Vermeulen A,Liu J,de Greef R,Groothuis GM,Danhof M,Proost JH

更新日期：2012-04-01 00:00:00

abstract：:Intraventricular administration of chemotherapy is one approach to overcoming the limited distribution of anticancer drugs and their active metabolites into the CNS. This form of regional chemotherapy has led to effective treatment of occult and overt meningeal leukaemia in humans. In contrast, the efficacy of this th...

journal_title：Clinical pharmacokinetics

authors： Fleischhack G,Jaehde U,Bode U

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone ace...

journal_title：Clinical pharmacokinetics

authors： Xu XS,Ryan CJ,Stuyckens K,Smith MR,Saad F,Griffin TW,Park YC,Yu MK,De Porre P,Vermeulen A,Poggesi I,Nandy P

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:This study proposes a model-informed approach for therapeutic drug monitoring (TDM) of rifampicin to improve tuberculosis (TB) treatment. METHODS:Two datasets from pulmonary TB patients were used: a pharmacokinetic study (34 patients, 373 samples), and TDM data (96 patients, 391 samples) colle...

journal_title：Clinical pharmacokinetics

authors： van Beek SW,Ter Heine R,Keizer RJ,Magis-Escurra C,Aarnoutse RE,Svensson EM

更新日期：2019-06-01 00:00:00

abstract：OBJECTIVE:Although amikacin is primarily eliminated via glomerular filtration, drug concentrations are not consistently predicted in all patients. To better describe the relationship between amikacin clearance and both age and renal function, we used a new heuristic approach involving statistical analysis of dependence...

journal_title：Clinical pharmacokinetics

authors： Ducher M,Maire P,Cerutti C,Bourhis Y,Foltz F,Sorensen P,Jelliffe R,Fauvel JP

更新日期：2001-01-01 00:00:00

abstract：:With the use of combination chemotherapy as well as a wide range of symptomatic therapies (e.g. analgesics and antiemetics) for the treatment of patients with cancer, the field of oncology practises polypharmacy to an extreme degree. The risk for a drug interaction under these conditions is high, and the pharmacologic...

journal_title：Clinical pharmacokinetics

authors： Balis FM

更新日期：1986-05-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals. METHODS:Samples for pharmacokinetic anal...

journal_title：Clinical pharmacokinetics

authors： Overgaard RV,Petri KC,Jacobsen LV,Jensen CB

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Dosing of therapeutic monoclonal antibodies (mAbs) is often based on body size, with the perception that body size-based dosing would reduce inter-subject variability in drug exposure. However, most mAbs are target specific with a relatively large therapeutic window and generally a small contri...

journal_title：Clinical pharmacokinetics

authors： Bai S,Jorga K,Xin Y,Jin D,Zheng Y,Damico-Beyer LA,Gupta M,Tang M,Allison DE,Lu D,Zhang Y,Joshi A,Dresser MJ

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Taurolidine is known to have antimicrobial activity. Furthermore, at lower concentrations, it has been found to exert a selective antineoplastic effect in vitro and in vivo. The aim of this study was to investigate the pharmacokinetics of taurolidine in vivo following repeated intravenous infus...

journal_title：Clinical pharmacokinetics

authors： Stendel R,Scheurer L,Schlatterer K,Stalder U,Pfirrmann RW,Fiss I,Möhler H,Bigler L

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:To assess the differences between patients with hepatic insufficiency and healthy subjects with regard to the pharmacokinetics, cardiac safety and overall safety of ebastine and its active metabolite carebastine. DESIGN:Open-label parallel-group study. PARTICIPANTS:24 patients with varying degrees of hepati...

journal_title：Clinical pharmacokinetics

authors： Lasseter KC,Dilzer SC,Vargas R,Waldman S,Noveck RJ

更新日期：2004-01-01 00:00:00

abstract：:First-pass elimination takes place when a drug is metabolised between its site of administration and the site of sampling for measurement of drug concentration. Clinically, first-pass metabolism is important when the fraction of the dose administered that escapes metabolism is small and variable. The liver is usually ...

journal_title：Clinical pharmacokinetics

authors： Pond SM,Tozer TN

更新日期：1984-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Escitalopram is one of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs). It is thought to act by blocking the serotonin transporter (SERT). However, its dose-SERT occupancy relationship is not well known, so it is not clear what level of SERT blockade is achieved by ...

journal_title：Clinical pharmacokinetics

authors： Kim E,Howes OD,Kim BH,Chon MW,Seo S,Turkheimer FE,Lee JS,Lee YS,Kwon JS

更新日期：2017-04-01 00:00:00